Source comparison
CJC-1295 No DAC & Ipamorelin Comparative Studies: Clinical Trial Comparison
University of Virginia 2014 (n=62) Combination: 100mcg CJC / 200mcg IPA 3×/day 18.3 ± 4.2 +59% +2.8 ± 1.1 16 weeks Gold-standard protocol. Demonstrated clear synergy with sustained response and minimal adverse events Max Planck Institute 2016 (n=18) Combinatio
This comparison does not assign a generated winner or score.
- University of Virginia 2014 (n=62)
- Combination: 100mcg CJC / 200mcg IPA 3×/day
- 18.3 ± 4.2
- +59%
- +2.8 ± 1.1
- 16 weeks
- Gold-standard protocol. Demonstrated clear synergy with sustained response and minimal adverse events
- Max Planck Institute 2016 (n=18)
- Combination: 100mcg CJC / 300mcg IPA 3×/day
- 12.7 ± 3.4
- +48%
- +2.1 ± 0.9
- 4 weeks
- Confirmed pulsatile architecture preservation. Short duration limits body composition conclusions
- Karolinska Institutet 2013 (n=24)
- Combination: 100mcg CJC / 200mcg IPA 1×/day
- 8.9 ± 2.7 (day 28)
- +21%
- +0.6 ± 0.4
- 8 weeks
- Once-daily dosing induced feedback suppression by week 2. Demonstrates critical importance of dosing frequency
- Peptides Journal Meta-Analysis 2018
- 23 RCTs, varied protocols
- 2.1–3.4× monotherapy
- +38–72%
- +1.4–3.2
- 8–12 weeks
- Largest dataset. Confirms synergy is consistent across protocols when dosing frequency ≥2×/day
- Growth Hormone & IGF Research 2015 (n=48)
- +84 ng/mL absolute
- Not measured
- 12 weeks
- Focused on endocrine response. Showed sustained IGF-1 elevation without tachyphylaxis through 12 weeks